EA200300474A1 - ESTROGEN RECEPTOR MODULATORS - Google Patents
ESTROGEN RECEPTOR MODULATORSInfo
- Publication number
- EA200300474A1 EA200300474A1 EA200300474A EA200300474A EA200300474A1 EA 200300474 A1 EA200300474 A1 EA 200300474A1 EA 200300474 A EA200300474 A EA 200300474A EA 200300474 A EA200300474 A EA 200300474A EA 200300474 A1 EA200300474 A1 EA 200300474A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- estrogen
- present
- estrogen receptors
- estrogen receptor
- Prior art date
Links
- 239000002834 estrogen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000015694 estrogen receptors Human genes 0.000 abstract 2
- 108010038795 estrogen receptors Proteins 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 206010021639 Incontinence Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 201000000079 gynecomastia Diseases 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000005075 mammary gland Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 abstract 1
- 201000007954 uterine fibroid Diseases 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Настоящее изобретение относится к соединениям и их производным, способам их получения и их использованию в качестве модуляторов рецепторов эстрогена. Соединения настоящего изобретения являются лигандами для рецепторов эстрогена и как таковые могут быть полезными для лечения или профилактики различных состояний, относящихся к функционированию эстрогена, включающих: потерю костной массы, переломы костей, остеопороз, дегенерацию хрящей, эндометриоз, фиброидное заболевание матки, приступообразное ощущение жара, повышенные уровни холестерина LDL, сердечно-сосудистое заболевание, недостаточность когнитивной деятельности, церебральные дегенеративные нарушения, рестеноз, гинекомастию, пролиферацию клеток гладких мышц сосудов, ожирение, недержание и рак, особенно молочной железы, матки и простаты.Отчет о международном поиске был опубликован 2002.08.22.The present invention relates to compounds and their derivatives, methods for their preparation and their use as modulators of estrogen receptors. The compounds of the present invention are ligands for estrogen receptors and, as such, may be useful for treating or preventing various conditions relating to the functioning of estrogen, including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, elevated LDL cholesterol levels, cardiovascular disease, cognitive insufficiency, cerebral degenerative disorders, restenosis, gynecomastia, n the role of the vascular smooth muscle cell carriage, obesity, incontinence, and cancer, especially of the mammary gland, uterus, and prostate. The international search report was published on 2002.08.22.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24158200P | 2000-10-19 | 2000-10-19 | |
| PCT/US2001/042735 WO2002032377A2 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200300474A1 true EA200300474A1 (en) | 2003-10-30 |
Family
ID=22911282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200300474A EA200300474A1 (en) | 2000-10-19 | 2001-10-15 | ESTROGEN RECEPTOR MODULATORS |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1333827A2 (en) |
| JP (1) | JP2004511502A (en) |
| KR (1) | KR20030042020A (en) |
| CN (1) | CN1469743A (en) |
| AU (2) | AU2002232381B2 (en) |
| BG (1) | BG107676A (en) |
| BR (1) | BR0114689A (en) |
| CA (1) | CA2424729A1 (en) |
| EA (1) | EA200300474A1 (en) |
| EC (1) | ECSP034558A (en) |
| EE (1) | EE200300153A (en) |
| HU (1) | HUP0303563A2 (en) |
| IL (1) | IL154984A0 (en) |
| IS (1) | IS6761A (en) |
| MX (1) | MXPA03003485A (en) |
| NO (1) | NO20031737L (en) |
| PE (1) | PE20021083A1 (en) |
| PL (1) | PL361053A1 (en) |
| SK (1) | SK4772003A3 (en) |
| WO (1) | WO2002032377A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| EP1501819B1 (en) | 2002-04-24 | 2010-09-15 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
| DE60317061T2 (en) | 2002-05-10 | 2008-07-24 | F. Hoffmann-La Roche Ag | IBANDRONIC ACID FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS |
| AU2003292625B2 (en) * | 2002-12-26 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Selective estrogen receptor modulators |
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| CA2627139A1 (en) * | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
| AU2007345526B2 (en) | 2007-02-01 | 2013-02-28 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| AU2010204106B2 (en) | 2009-01-08 | 2014-05-08 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| MX392179B (en) | 2009-03-18 | 2025-03-21 | Resverlogix Corp | NEW ANTI-INFLAMMATORY AGENTS. |
| TR201818390T4 (en) | 2009-04-22 | 2019-01-21 | Resverlogix Corp | NEW ANTI-INFLAMMATORY AGENTS |
| MX2012014431A (en) | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | MODULAR RECEPTOR OF STROGENS AND USES OF THE SAME. |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| ES2745471T3 (en) | 2011-11-01 | 2020-03-02 | Resverlogix Corp | Oral immediate-release formulations for substituted quinazolinones |
| JP2015500346A (en) | 2011-12-14 | 2015-01-05 | セラゴン ファーマシューティカルズ，インク． | Estrogen receptor modulators and uses thereof |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| EP2935253B1 (en) | 2012-12-21 | 2018-08-01 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| KR102662814B1 (en) | 2015-03-13 | 2024-05-03 | 리스버로직스 코퍼레이션 | Compositions and treatment methods for treating complement-related diseases |
-
2001
- 2001-10-15 IL IL15498401A patent/IL154984A0/en unknown
- 2001-10-15 AU AU2002232381A patent/AU2002232381B2/en not_active Ceased
- 2001-10-15 BR BR0114689-0A patent/BR0114689A/en not_active Application Discontinuation
- 2001-10-15 EA EA200300474A patent/EA200300474A1/en unknown
- 2001-10-15 WO PCT/US2001/042735 patent/WO2002032377A2/en not_active Ceased
- 2001-10-15 AU AU3238102A patent/AU3238102A/en active Pending
- 2001-10-15 MX MXPA03003485A patent/MXPA03003485A/en unknown
- 2001-10-15 CN CNA018176720A patent/CN1469743A/en active Pending
- 2001-10-15 JP JP2002535616A patent/JP2004511502A/en not_active Withdrawn
- 2001-10-15 EP EP01987654A patent/EP1333827A2/en not_active Withdrawn
- 2001-10-15 SK SK477-2003A patent/SK4772003A3/en unknown
- 2001-10-15 EE EEP200300153A patent/EE200300153A/en unknown
- 2001-10-15 CA CA002424729A patent/CA2424729A1/en not_active Abandoned
- 2001-10-15 KR KR10-2003-7005518A patent/KR20030042020A/en not_active Withdrawn
- 2001-10-15 HU HU0303563A patent/HUP0303563A2/en unknown
- 2001-10-15 PL PL01361053A patent/PL361053A1/en not_active Application Discontinuation
-
2002
- 2002-04-15 PE PE2002000308A patent/PE20021083A1/en not_active Application Discontinuation
-
2003
- 2003-03-26 BG BG107676A patent/BG107676A/en unknown
- 2003-03-27 IS IS6761A patent/IS6761A/en unknown
- 2003-04-15 NO NO20031737A patent/NO20031737L/en unknown
- 2003-04-17 EC EC2003004558A patent/ECSP034558A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IS6761A (en) | 2003-03-27 |
| BR0114689A (en) | 2003-07-01 |
| HUP0303563A2 (en) | 2004-03-01 |
| SK4772003A3 (en) | 2003-08-05 |
| MXPA03003485A (en) | 2003-07-14 |
| CN1469743A (en) | 2004-01-21 |
| PE20021083A1 (en) | 2002-12-16 |
| ECSP034558A (en) | 2003-06-25 |
| PL361053A1 (en) | 2004-09-20 |
| EP1333827A2 (en) | 2003-08-13 |
| AU3238102A (en) | 2002-04-29 |
| WO2002032377A3 (en) | 2002-08-22 |
| WO2002032377A2 (en) | 2002-04-25 |
| KR20030042020A (en) | 2003-05-27 |
| NO20031737L (en) | 2003-06-19 |
| EE200300153A (en) | 2003-06-16 |
| IL154984A0 (en) | 2003-10-31 |
| BG107676A (en) | 2003-11-28 |
| CA2424729A1 (en) | 2002-04-25 |
| AU2002232381B2 (en) | 2004-11-18 |
| JP2004511502A (en) | 2004-04-15 |
| NO20031737D0 (en) | 2003-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200300474A1 (en) | ESTROGEN RECEPTOR MODULATORS | |
| EP1501819A4 (en) | OESTROGENE RECEPTOR MODULATORS | |
| ATE524170T1 (en) | ESTROGEN RECEPTOR MODULATORS | |
| WO2002091993A3 (en) | Estrogen receptor modulators | |
| ATE329904T1 (en) | ESTROGEN RECEPTOR MODULATORS | |
| NO20072771L (en) | estrogen | |
| MX2007006878A (en) | Estrogen receptor modulators. | |
| DE69935335D1 (en) | PYRAZOLE AS MODULATORS OF THE ESTROGEN RECEPTOR | |
| WO2004073612A3 (en) | Estrogen receptor modulators | |
| PT1140889E (en) | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | |
| PT1246814E (en) | COMPOUNDS AND METHODS FOR THE MODULATION OF ESTRGEN RECEPTORS | |
| WO2004091488A3 (en) | Estrogen receptor modulators | |
| WO2002032373A3 (en) | Estrogen receptor modulators | |
| AR039282A1 (en) | STROGEN RECEIVERS MODULATORS | |
| DE60112624D1 (en) | ESTROGEN RECEPTOR LIGANDS AND METHOD | |
| WO2006081152A3 (en) | Estrogen receptor modulators | |
| ATE517871T1 (en) | ESTROGEN RECEPTOR MODULATORS | |
| WO2002058639A3 (en) | Pyranoflavonoid compounds and their use as estrogen receptor modulators | |
| WO2004073610A3 (en) | Estrogen receptor modulators | |
| WO2004026887A3 (en) | Estrogen receptor modulators | |
| WO2008057309A3 (en) | Estrogen receptor modulators | |
| DOP2002000384A (en) | MODULATORS OF ESTROGEN RECEPTORS. | |
| DOP2005000224A (en) | MODULATORS OF STROGEN RECEIVERS |